Roivant Sciences files Form 144 for 200,000 shares

Roivant Sciences Ltd. submitted a Form 144 disclosing a proposed sale of 200,000 common shares tied to an Options Exercise - Grant Date 05/22/2026.

Rhea-AI Filing Summary

Roivant Sciences Ltd. submitted a Form 144 disclosing a proposed sale of 200,000 common shares tied to an Options Exercise - Grant Date 05/22/2026. The filing lists a sale date of 05/22/2026 for those shares.

The filing also records recent sales by Eric Venker: 7,051 common shares on 02/20/2026 for $191,434.65, 200,000 common shares on 03/17/2026 for $5,648,836.44, and 200,000 common shares on 04/20/2026 for $5,917,134.05.

Insights

Securities Counsel

Form 144 notifies the SEC of an intended sale of 200,000 shares tied to an options exercise.

The notice indicates an Options Exercise - Grant Date 05/22/2026 and a proposed sale date of 05/22/2026. Form 144 is a disclosure of intent to sell by an affiliated party and does not itself effect a sale.

Timing, placement method, and who receives proceeds are not specified in the excerpt; subsequent transaction filings will show execution details and final purchasers.

Key Figures

Proposed shares to be sold: 200,000 shares Proposed sale date: 05/22/2026 Prior sale (Feb): 7,051 shares +2 more

5 metrics

Proposed shares to be sold 200,000 shares tied to Options Exercise - Grant Date 05/22/2026

Proposed sale date 05/22/2026 date listed for the 200,000-share sale

Prior sale (Feb) 7,051 shares sale on 02/20/2026 for $191,434.65

Prior sale (Mar) 200,000 shares sale on 03/17/2026 for $5,648,836.44

Prior sale (Apr) 200,000 shares sale on 04/20/2026 for $5,917,134.05

Key Terms

Form 144, Options Exercise - Grant Date, Common Shares

3 terms

Form 144 regulatory

"submitted a Form 144 disclosing a proposed sale"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Options Exercise - Grant Date financial

"Options Exercise - Grant Date 05/22/2026"

Common Shares financial

"Common Shares | 05/22/2026 | Options Exercise"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Roivant's Form 144 disclose (ROIV)?

It discloses a proposed sale of 200,000 common shares tied to an options exercise with grant date 05/22/2026. The filing shows the sale date as 05/22/2026.

Who sold shares recently according to the filing for ROIV?

The filing lists recent sales by Eric Venker: 7,051 shares on 02/20/2026, 200,000 shares on 03/17/2026, and 200,000 shares on 04/20/2026. Each sale includes the dollar amounts shown.

Are proceeds recipients or placement details shown in the Form 144 for ROIV?

Proceeds recipients and placement mechanics are not specified in the excerpt. The notice lists sale quantities, dates, and corresponding dollar figures but not purchaser or use-of-proceeds details.

Does the Form 144 finalize a sale for ROIV?

No. The Form 144 notifies of an intended sale; it does not complete the transaction. Execution details and final reporting would appear in subsequent trade or Form 4/5 filings if applicable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 04:00 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Venker Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	200000	6054730.92	719270385	05/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	05/22/2026	Options Exercise - Grant Date 05/22/2026	Roivant Sciences Ltd.			200000	05/22/2026	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1H0DB	Common	02/20/2026	7051	191434.65
Eeric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	04/20/2026	200000	5917134.05
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	03/17/2026	200000	5648836.44

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/28/2025.
Date of Notice	05/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/28/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Heather Virgoe as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Eric Venker
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)